Paul Payette

TL;DR: In this article, the mouse homolog of the gene encoding PTP-1B yielded healthy mice that, in the fed state, had blood glucose concentrations that were slightly lower and concentrations of circulating insulin that were one-half those of their PTP−1B+/+ littermates.

TL;DR: The results show that vanadate is a competitive inhibitor for the protein-tyrosine phosphatase PTP1B, with a Ki of 0.38 ± 0.02 μM, and reducing agents such as dithiothreitol that are used in PTP assays to keep the catalytic cysteine reduced and active were found to convert pervanadate rapidly toVanadate.

TL;DR: The identification of this mutation should not only help define the physiological role of sPLA2 but also has important implications in mouse inflammatory models developed by targeted mutagenesis.

TL;DR: In vitro results for CYP 3A1/2 and 2B 1/2 induction correlated well with those observed in vivo, and should facilitate the demand for a fast and reproducible method for addressing P450 induction by numerous compounds at the drug discovery stage.

TL;DR: Evidence is presented to show that the hydroxyl group of Ser-228 is the catalytic nucleophile of cPLA2 and that cysteine can replace serine as the nucleophile, resulting in a thiol-cPLA2 with significantly reduced catalytic power.